In March 2020, the UK government announced that it would be launching a national testing effort to support the UK’s fight against coronavirus via the establishment of a network of “mega” testing laboratories, known as “Lighthouse Labs”.
Medicines Discovery Catapult were tasked with the challenge of coordinating the creation of the UK’s Lighthouse Labs Network and delivery of one of those labs, based at Alderley Park in Cheshire.
Professor Chris Molloy, Medicines Discovery Catapult CEO, was appointed Director of the UK Lighthouse Labs Network and Professor Peter Simpson, Medicines Discovery Catapult CSO, was appointed Director of the Alderley Park Laboratory.
The Lighthouse Labs take their name from the PCR testing technology which uses fluorescent light to detect the virus.
Universities, research institutes and commercial companies across the UK lent testing equipment and expertise in response to this vital national need.
Our leadership team was formed during unprecedented circumstances to support the UK’s national requirement for COVID-19 testing. Meet the leadership team >
We have a range of scientific and operational roles. View all of the current Lighthouse Labs vacancies >